(secondQuint)Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial.

 This is an open-label, international, Phase 3 study evaluating the efficacy and safety of the S-1/cisplatin regimen versus the 5-FU/cisplatin regimen in chemotherapy-naive patients with metastatic diffuse gastric carcinoma including carcinoma of the gastro-esophageal junction.

 Patients will be randomly assigned to S-1/cisplatin (experimental regimen, Arm A) or 5-FU/cisplatin (control regimen, Arm B).

.

 Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial@highlight

The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and esophagogastric junction cancer previously untreated with chemotherapy.

